PharmNovo

PHARMNOVO AIMS TO CREATE novel drugs with superior clinical properties to treat patients with chronic pain using our knowledge and experience of drug design and G protein-coupled receptor pharmacology. Our specific target is the delta opioid receptor (DOR).

PharmNovo’s aim is to target the multiple disease areas of chronic pain, including neuropathic, osteoarthritic and migraine pain and the commonly associated conditions of anxiety and depression. These disease areas have mechanistic commonalities susceptible to the company’s novel approach to drug discovery.

Internationally Pharmnovo collaborate with several academic institutions. University of Bristol to study mechanism related to delta opioid receptors and University of Illinois to investigate migraine related diseases.